Tag Archives: biopharmaceutical manufacturing

Sentry team to participate in the 2019 Susan G. Komen Race for the Cure ®

This Saturday, April 27th, 2019 several Sentry BioPharma Services team members will be proudly participating in the 2019 Komen Central Indiana Race for the Cure ®. 

Over the years this event has raised more than $2 billion dollars to help fund research, education, screening and treatment.  This event is unique in that 100% of the net proceeds are invested in the Komen mission.  25% of all funds go towards research to learn about the biology of breast cancer, advance new screening technologies, develop better treatment protocols and combat metastatic disease.  The remaining 75% is invested in locally through a community grants program.  Last year $697,047 was invested in 9 local breast health programs and provide 40,000 services within a 41-county service area in Indiana.

Our team realizes that fundraising is critical to helping breast cancer patients living right here in central Indiana.  These sobering statistics from the Central Indiana Susan G. Komen website help to bring that need even more into focus.

  • 1 in 8 women in the U.S. will be diagnosed with breast cancer in her lifetime.
  • Every 19 seconds, somewhere in the world, a case of breast cancer is diagnosed.
  • Every 60 seconds, somewhere in the world, someone dies from breast cancer.
  • Every 13 minutes, one woman in the U.S will lose her life to breast cancer.
  • At the current rate, 13 million breast cancer deaths will occur around the world in the next 25 years.

Sentry is determined to take action and this event is our chance to support the Komen organization in its efforts to end breast cancer forever. 

For more info on how you can help please visit the Susan G. Komen® website.

Consultants Day at Vetter Development Services

Sentry BioPharma Services was pleased to be invited to speak at Vetter Development Services, Consultant Day which took place in Chicago, IL on June 22, 2016.

The theme for the conference was “Your Molecule’s Journey”.  The objective of the conference was to inform pharmaceutical consultants of the unified service offerings of Sentry and Vetter (see diagram below).  The combined services take a molecule after discovery from formulation to end patient.  Alongside Vetter’s and Sentry’s presentations were talks by CMC Biologics on drug discovery and development and by FedEx Custom Critical on issues surrounding drug distribution and delivery worldwide.

Sentry Vetter Brochure P2

Vetter Development Services, Inc., located in Skokie, Illinois, is a premier contract development and manufacturing organization (CDMO).  Vetter is a global leader in the fill & finish contract manufacturing of aseptically prefilled syringe systems, cartridges, and vials. It is a family-owned, independent company with facilities both in Germany and the US, as well as offices in Singapore and Japan. Vetter’s focus is on providing state-of-the-art biopharmaceutical manufacturing, from early clinical development and scale-up to commercial filling and packaging of parenteral drugs. They provide support every step of the way, guiding your drug product through development, regulatory approval, launch, and life cycle management. Vetter offers biotech and pharmaceutical companies a foundation of experience spanning more than 35 years including dozens of product approvals for novel pharmaceutical and biotech compounds.

Mr. Tim J. Mitchell, President of Sentry BioPharma Services, presented a talk entitled:  “Protecting Product Integrity Throughout the Supply Chain”.  Mr. Mitchell had this to say about the meeting, “Through our many years of experience at Sentry we have encountered numerous issues arising from the supply chain of drug products.  I shared several stories and this example highlights the key points of my talk.”

A few years ago a large multinational pharmaceutical company (“LMP”), which is a Sentry client today, contacted Sentry concerning the +2°C to +8°C GMP storage and distribution of a sizable quantity of a new commercial vaccine which was to be imported from Europe.  We were told that LMP would handle all pharmaceutical cold chain logistics activities and we should be ready to receive the product on a certain date.  The receipt date came and went with no vaccine delivery.

The vaccine was held up in customs at O’Hare International Airport, the port of entry.  Ten days go by and finally the product arrives at Sentry.  There was concern about the vaccine strength, identity, safety, purity and quality (SISPQ) because the LMP knew that the temperature data loggers would have stopped working days earlier.  However, this issue became moot.

The pharmaceutical company ultimately had hired “Bob’s Trucking” to pick up the vaccine at O’Hare and delivery it to Sentry.  The shipping manifest called for a refrigerated truck with a temperature set point of +5°C.  Unfortunately, Bob was unclear on the differences between Centigrade and Fahrenheit so he placed the shipment in a reefer truck with a temperature set point of +5°F.

“It is a dismal situation for a company to devote the significant resources to develop and manufacture an expensive medication which can save lives and have it all ruined by avoidable mistakes during the last miles of the pharmaceutical supply chain to patients,” Mr. Mitchell pointed out.

“The scenario above is too common today regardless of present day technical advancements.  Sentry’s foreign trade zone (FTZ) could have provided a different and much better outcome for the vaccine distribution process.  Instead of clearing customs at the airport, the vaccine could have been sent directly to Sentry and placed in its validated +2°C to +8°C GMP storage environment.  While at Sentry, the product could have cleared customs and obtained FDA approval.  Once this was accomplished the vaccine would have entered U.S. commerce and could have been distributed to hospitals, clinics and ultimately to patients.”

Sentry BioPharma Services is a contract service organization (CSO) which supports the life science industry by offering GMP temperature-controlled storage, global drug distribution, FDA-compliant labeling and packaging services and importation support utilizing Sentry’s Foreign Trade Zone (FTZ).  Drug development and commercialization require continuous temperature monitoring and control.  Sentry’s diverse offerings protect product integrity throughout the pharmaceutical supply chain.  Sentry’s validated software, GMP storage and drug distribution facility, industry expertise and stringent quality standards support this objective throughout manufacturing, packaging, storage and distribution.

To learn more about how Sentry BioPharma Services can protect your products’ integrity throughout the pharmaceutical supply chain, please, contact Sentry via email or by phone at 1-866-757-7400.

Sentry Successfully Launches New Website

Sentry BioPharma Services is very excited to announce the launch of our newly designed website. The site’s homepage fully embraces Sentry’s brand while showcasing an elegant design while providing intuitive navigation. The newly streamlined menus highlight Sentry’s main services from vaccine distribution and GMP pharmaceutical storage to custom solutions such as biopharmaceutical labeling and packaging, controlled substance distribution and our foreign trade zone (FTZ) offering.

One of the most noticeable changes is the full integration our company logo, the Sentry molecule.  Each atom organizes Sentry’s services into five main categories:  temperature, packaging, distribution, clinical trials and custom solutions all of which are held together by Sentry’s stringent quality standards and GMP storage and drug distribution expertise. The ”Learn More” buttons under each service category allow customers easy access to relevant details regarding Sentry’s biorepository and drug distribution capabilities to include controlled substance importation and exportation, API storage, clinical trial labeling and packaging.

“With the changing ways in which information is viewed on the Internet, we wanted to provide a consistent experience across many types of devices.  Our new website is designed using “Responsive Web Design“.  This provides an optimal viewing experience across a wide range of devices, from computer monitors, to tablets and phones.” – Mike Wilson, Information Technology Manager

“As a biopharmaceutical leader, it’s important for us to make information regarding solutions, services and trends easily accessible for our current and prospective clients. We endeavor to provide our clients with the most accurate, up-to-date information and share our knowledge and expertise in the field of temperature- sensitive product management.” – Tim Mitchell, President

“Sentry is a biopharmaceutical contract service provider which maintains an exceptional quality record and provides superior customer service. Our new site is an extension of that service and we are excited to have a platform the effectively reflects our dedication to providing outstanding quality to our clients in every facet of our business and throughout the pharmaceutical supply chain.” – Jennifer Marcum, Chief Executive Officer

For more information about how Sentry can help optimize your solutions for biopharmaceutical product storage, drug distribution, clinical trial packaging and commercial fulfillment, contact Sentry via email or by phone at 1-866-757-7400.

Sentry Helps the DEA to Raise Public Awareness about the 11th National Prescription Drug Take-Back Day Initiative

As part of the U.S. Drug Enforcement Administration’s (DEA’s) National Prescription Drug Take-Back Day Initiative (NTBI), people will be able to dispose of expired, unwanted or unused prescription drugs on Saturday, April 30, 2016 from 10:00 a.m. to 2:00 p.m. at numerous collection sites around the U.S.

“The DEA’s program is designed to focus national attention on the proper disposal of prescription drugs and controlled substances,” said Ms. Jennifer Marcum, Sentry BioPharma Services’ chief executive officer.  Marcum continued, “During the event, people can bring their unwanted prescription pharmaceuticals and over-the-counter (OTC) medications to a participating drop-off site for proper drug disposal by law enforcement authorities with no questions asked.  The service is not only free and anonymous, but also an ideal way to preserve the environment from unwanted pharmaceutical contamination.  This is a terrific opportunity for those who missed the previous events, or who have subsequently accumulated unwanted, unused prescription drugs, to safely dispose of those medications.”

Americans that participated in the DEA’s tenth annual National Prescription Drug Take-Back Day on September 26, 2015, turned in more than 350 tons of unwanted or expired medications for safe and proper drug disposal at more than 5,000 take-back collections sites available in all 50 states and U.S. territories.  When the results of the ten prior Take-Back Days are combined, the DEA, and its state, local, and tribal law-enforcement and community partners have removed 5,525,021 pounds of drugs from circulation.

“The numbers are shocking—approximately 46,000 Americans die each year from drug-related deaths.  More than half of those are from heroin and prescription opioids,” said Acting DEA Administrator Chuck Rosenberg.  “With four out of five new heroin users starting with prescription medications, I know our take-back program makes a real difference.”  The NTBI addresses a crucial public safety and public health issue.  According to the 2014 National Survey on Drug Use and Health, 6.5 million Americans abused controlled prescription drugs.  That same study showed that a majority of abused prescription drugs are obtained from family and friends, including from the home medicine cabinet.  The DEA’s NTBI events are also a significant piece of the White House Office of National Drug Control Policy’s prescription drug abuse prevention strategy.

Sentry BioPharma Services will also continue its support of the DEA’s efforts by helping to raise public awareness of this important initiative.  For more information about the drug disposal program, general public inquiries can be made by calling the DEA toll free at: 1-800-882-9539.

Sentry BioPharma Services’ Employees Make a Declaration to Fight Breast Cancer

Did you know that one in eight women in the U.S. will be diagnosed with breast cancer in her lifetime?  At this current rate 13 million breast cancer deaths around the world will occur in the next 25 years.

While certain factors affect prognosis (chance of recovery) and treatment options, research on the biology of cancer is necessary to answer the most basic questions about what is and what is not normal.  The outcomes of basic research in cancer biology are often uncertain, which makes oncology funding from profit-driven sources a risky undertaking.

On December 19, 2015 the National Institutes of Health (NIH) received a nearly $2 billion increase in funding for FY16 by way of approval of the Omnibus Appropriations Bill.  The bill provided for continued funding for the Department of Defense’s Breast Cancer Research Program.   Despite the increase, the National Cancer Institute’s (NCI’s) budget falls $238 million short of the $5.5 billion the institute requested for the fiscal year 2017 budget.  Federal funding helps but is simply not enough to develop the arsenal of tools and strategies needed for sharing and communicating about oncology research results.  More help is needed to fight this battle!

Amber M. Reed, Sentry BioPharma Services’ Warehouse Supervisor, declares her commitment to be a “Pink Warrior” by participating in the 25th Anniversary Komen Central Indiana Race for the Cure® on Saturday, April 16, 2016 commencing at the historic Military Park in downtown Indianapolis, Indiana.  Ms. Reed says, “I have lost my grandmother and great-grandmother to breast cancer. My grandmother was like a mother to me. Since her passing in 2006 I have pledged to do whatever I can to help in the research to find a cure for this awful disease. I have participated in either Relay for Life® or Race for the Cure® every year since. I love the fact that I work for a company that also shares my dedication in helping to find a cure for cancer. Together I believe we can make cancer a thing of the past.”

According to the race sponsor’s website, “the Susan G. Komen Race for the Cure® Series is the world’s largest and most successful education and fundraising event for breast cancer ever created.  The event raises significant funds and awareness for the breast cancer movement, celebrates breast cancer survivorship and honors those who have lost their battle with the disease.

This race is unique in the fact that 100% of the net proceeds are allocated to our mission. Seventy-five percent of the net income stays in our community to help fund local programs offering breast health education and breast cancer screening and treatment. The remaining 25% of the net income supports the Susan G. Komen® Grants Program.

Sentry BioPharma Services supports Ms. Reed’s efforts and commits to helping raise public awareness of this important cause.  The company pledges on-going help to vaccine manufacturers by offering reliable GMP warehousing and drug distribution services to eliminate variables in oncology clinical trials in hope of one day eradicating this deadly disease.

 

Warehouse Coordinator Chris Harris and Chief Operations Officer Dwayne Marcum

Warehouse Coordinator Chris Harris and Chief Operations Officer Dwayne Marcum

IMG_0056

Left to right: Warehouse Supervisor Amber Reed, Inside Sales Representative Jasmine Enlow, Chief Executive Officer Jennifer Marcum, Warehouse Coordinator Chris Harris

IMG_0614

Sentry BioPharma Services Confirms Attendance at BIO 2016 in San Francisco, California

Sentry BioPharma Services returns to the birthplace of biotech, San Francisco, California in June 2016. This marks Sentry’s 11th consecutive year attending the Biotechnology Innovation Organization’s (BIO’s) International Convention. Sentry leadership selects this conference annually primarily because it attracts over 15,000 biotechnology and pharma representatives from all over the world who unite for one week in the U.S. The topics discussed during this event and in the exhibit hall cover a wide spectrum of relevant life science topics as well as areas like drug discovery, GMP compliance, bio-manufacturing, genomics and cell therapy.

“BIO One-on-One Partnering™ serves as a cost effective way to interact globally without the extensive international traveling requirements” states Sentry’s President, Tim J. Mitchell. “There are 3,100+ companies participating in these meetings. We find the online scheduling tool to be exceptionally user-friendly and effective which allows us to interact with a vast number of prospective pharmaceutical partners and companies developing biological products. We efficiently present information concerning our customized pharmaceutical labeling, packaging and kitting processes. We also entertain numerous questions concerning Sentry’s international drug distribution services in the pavilions and/or at booths in the exhibit hall, all within the allotted 25-minute time frame. It’s amazing what can be accomplished in 3 1/2 days at BIO!”

The BIO One-in-One Partnering™ feature allows Sentry’s leaders to network and discover new opportunities and potential partnerships. Please meet us at the 2016 BIO International Convention in San Francisco, USA.

Contact Sentry via email or by phone at 1-866-757-7400.

https://convention.bio.org/2016/